US EditionAbivax climbs on Lilly takeover speculation
7 Articles
7 Articles
According to La Lettre, the US pharmaceutical giant would wait for "a sign" from the Ministry of Economy to acquire French biotech.
France's Ministry of Economy, Finance and Digital Sovereignty has denied having received a formal request for approval of the purchase of the Gaul Abivax laboratory by the American Eli Lilly, which disproves information appearing in the media.
Eli Lilly (LLY) Stock: Pharma Giant Eyes €15 Billion French Buyout
TLDR Eli Lilly preparing €15 billion acquisition offer for French biotech Abivax, awaiting French Finance Ministry guidance Tirzepatide generated $24.8 billion revenue in first nine months of 2025, becoming world’s best-selling drug Orforglipron oral weight loss treatment under priority review with decision expected by February 2026 Retatrutide achieved 28.7% mean weight loss in phase 3 trials, highest industry performance recorded Stock trades…
Abivax stock jumps on fresh Eli Lilly takeover talk as ABVX.PA hits record — what traders watch next
Paris, Jan 12, 2026, 11:17 CET — Regular session Shares in ABIVAX Société Anonyme surged Monday following a French media report that stirred new takeover speculation involving the biotech and U.S. pharmaceutical giant Eli Lilly. (Reuters) The stock climbed roughly 22% to 120.60 euros, hitting a peak of 130 euros earlier, based on Euronext-tracked quotes. It closed at 99 euros on Friday. (MarketScreener Canada) Why it matters now: Abivax is among…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
